<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03554304</url>
  </required_header>
  <id_info>
    <org_study_id>W-5222-103</org_study_id>
    <nct_id>NCT03554304</nct_id>
  </id_info>
  <brief_title>Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Double-Dummy, Placebo- and Positive-Controlled, Crossover Study to Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wockhardt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wockhardt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-Blind, Double-Dummy, Placebo- and Positive-Controlled, Crossover Study
      to Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 9, 2017</start_date>
  <completion_date type="Actual">October 6, 2017</completion_date>
  <primary_completion_date type="Actual">June 5, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of delay in cardiac repolarization induced by WCK 5222</measure>
    <time_frame>0-4 days</time_frame>
    <description>as shown by analysis of the QT interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events to assess tolerability at the supratherapeutic dose to be used in the thorough QT evaluation</measure>
    <time_frame>0-4 days</time_frame>
    <description>Tolerability will be assessed by review of number of AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs to assess the safety of high doses of single-dose administration of FEP-ZID</measure>
    <time_frame>0-4 days</time_frame>
    <description>Safety will be assessed by review of adverse events (AEs), ECGs, and clinical laboratory safety test results</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>QT/QTc Interval in Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>WCK 5222</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WCK 5222 IV solution administered as either a 30- or 60-minute IV infusion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (IV placebo matched toWCK 5222IV solution)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsule matched to moxifloxacin overencapsulated tablet IV placebo matched to WCK 5222 IV solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin 400-mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>positive control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WCK 5222</intervention_name>
    <description>FEP-ZID IV solution administered as either a 30- or 60-minute IV infusion)</description>
    <arm_group_label>WCK 5222</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV placebo matched to WCK 5222 / Moxifloxacin IV solution</intervention_name>
    <description>Placebo (IV placebo matched to FEP-ZID IV solution) and
1 placebo capsule matched to moxifloxacin overencapsulated tablet</description>
    <arm_group_label>Moxifloxacin 400-mg</arm_group_label>
    <arm_group_label>Placebo (IV placebo matched toWCK 5222IV solution)</arm_group_label>
    <arm_group_label>WCK 5222</arm_group_label>
    <other_name>Placebo capsule matched to moxifloxacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin 400-mg</intervention_name>
    <description>Moxifloxacin 400-mg positive control (overencapsulated tablet)</description>
    <arm_group_label>Moxifloxacin 400-mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Body mass index ≥18 to ≤33 kg/m2, inclusive.

          2. Stable health based on a medical history without any major pathology/surgery in the 6
             months

        Exclusion Criteria:

          1. An uninterpretable or abnormal screening electrocardiogram (ECG) indicating a second-
             or third-degree atrioventricular block

          2. History of risk factors for torsades de pointes, including unexplained syncope, known
             long QT syndrome, heart failure, myocardial infarction, angina, or clinically
             significant abnormal laboratory assessments including hypokalemia, hypocalcemia, or
             hypomagnesemia.

          3. A sustained supine systolic blood pressure &gt;150 mm Hg or &lt;90 mm Hg or a supine
             diastolic blood pressure &gt;95 mm Hg or &lt;50 mm Hg at Screening or Check-in (Day -1).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Spaulding Clinical Research</name>
      <address>
        <city>West Bend</city>
        <state>Wisconsin</state>
        <zip>53095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 16, 2018</study_first_submitted>
  <study_first_submitted_qc>May 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>May 30, 2018</last_update_submitted>
  <last_update_submitted_qc>May 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

